Education
About Us
Working with TipRanks
Follow Us
InnoCare Pharma Ltd. (HK:9969)
:9969
Total Valuation
InnoCare Pharma Ltd. has a market cap or net worth of HK$19.59B. The enterprise value is HK$0.00.
Market CapHK$19.59B
Enterprise ValueHK$0.00
Share Statistics
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,496,284,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCare Pharma Ltd.’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -6.14%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-6.14%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee926.95K
Profits Per Employee-415.60K
Employee Count1,089
Asset Turnover0.11
Inventory Turnover1.45
Valuation Ratios
The current PE Ratio of InnoCare Pharma Ltd. is ―. InnoCare Pharma Ltd.’s PEG ratio is 0.74.
PE Ratio―
PS Ratio9.63
PB Ratio1.45
Price to Fair Value1.45
Price to FCF-21.90
Price to Operating Cash Flow-100.64
PEG Ratio0.74
Income Statement
In the last 12 months, InnoCare Pharma Ltd. had revenue of 1.01B and earned -440.63M in profits. Earnings per share was -0.26.
Revenue1.01B
Gross Profit871.01M
Operating Income-525.78M
Pretax Income-452.59M
Net Income-440.63M
EBITDA-463.49M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -95.12M and capital expenditures -47.05M, giving a free cash flow of -142.17M billion.
Operating Cash Flow-95.12M
Free Cash Flow-142.17M
Free Cash Flow per Share-0.10
Dividends & Yields
InnoCare Pharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change116.69%
50-Day Moving Average14.16
200-Day Moving Average13.87
Relative Strength Index (RSI)38.20
Average Volume (3m)17.45M
Important Dates
InnoCare Pharma Ltd. upcoming earnings date is Mar 27, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 27, 2026
Ex-Dividend Date―
Financial Position
InnoCare Pharma Ltd. as a current ratio of 7.37, with Debt / Equity ratio of 18.29%
Current Ratio7.37
Quick Ratio7.28
Debt to Market Cap0.12
Net Debt to EBITDA10.68
Interest Coverage Ratio-15.56
Taxes
In the past 12 months, InnoCare Pharma Ltd. has paid 263.00K in taxes.
Income Tax263.00K
Effective Tax Rate>-0.01
Enterprise Valuation
InnoCare Pharma Ltd. EV to EBITDA ratio is -10.29, with an EV/FCF ratio of -10.74.
EV to Sales4.72
EV to EBITDA-10.29
EV to Free Cash Flow-10.74
EV to Operating Cash Flow-13.04
Balance Sheet
InnoCare Pharma Ltd. has HK$7.67B in cash and marketable securities with HK$1.82B in debt, giving a net cash position of HK$5.85B billion.
Cash & Marketable SecuritiesHK$7.67B
Total DebtHK$1.82B
Net CashHK$5.85B
Net Cash Per ShareHK$3.91
Tangible Book Value Per ShareHK$3.97
Margins
Gross margin is 88.27%, with operating margin of -52.09%, and net profit margin of -43.65%.
Gross Margin88.27%
Operating Margin-52.09%
Pretax Margin-44.84%
Net Profit Margin-43.65%
EBITDA Margin-45.91%
EBIT Margin-51.66%
Analyst Forecast
The average price target for InnoCare Pharma Ltd. is HK$20.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$20.15
Price Target Upside53.70% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast58.24%
EPS Growth Forecast38.85%